CCNE1 Antibody

說(shuō)明書(shū)

中文名稱(chēng)：

CCNE1兔多克隆抗體
貨號(hào)：

CSB-PA004817LA01HU
規(guī)格：

￥440
圖片：
Western Blot
Positive WB detected in: Mouse heart tissue, Mouse kidney tissue
All lanes: CCNE1 antibody at 3.2μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 48, 42, 46 kDa
Observed band size: 48 kDa

Immunohistochemistry of paraffin-embedded human testis tissue using CSB-PA004817LA01HU at dilution of 1:100
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱(chēng)：

Rabbit anti-Homo sapiens (Human) CCNE1 Polyclonal antibody
Uniprot No.：

P24864
基因名：

CCNE1
別名：

CCNE antibody; Ccne1 antibody; CCNE1_HUMAN antibody; cyclin E variant ex5del antibody; cyclin E variant ex7del antibody; Cyclin E1 antibody; Cyclin Es antibody; Cyclin Et antibody; CyclinE antibody; G1/S specific cyclin E antibody; G1/S-specific cyclin-E1 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human, Mouse
免疫原：

Recombinant Human G1/S-specific cyclin-E1 protein (8-105AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁(yè)面中的產(chǎn)品，CCNE1 Antibody (CSB-PA004817LA01HU)，的標(biāo)記方式是Non-conjugated。對(duì)于CCNE1 Antibody，我們還提供其他標(biāo)記。見(jiàn)下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱(chēng)	應(yīng)用
HRP	CSB-PA004817LB01HU	CCNE1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA004817LC01HU	CCNE1 Antibody, FITC conjugated
Biotin	CSB-PA004817LD01HU	CCNE1 Antibody, Biotin conjugated	ELISA

克隆類(lèi)型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Essential for the control of the cell cycle at the G1/S (start) transition.
基因功能參考文獻(xiàn)：
1. miR-874 inhibits CCNE1 expression during growth factor deprivation and that miR-874 down-regulation in osteosarcomas leads to CCNE1 up-regulation and more aggressive growth phenotypes. PMID: 29109143
2. Amplified/cyclin E1(hi) and non-amplified/cyclin E1(hi) tumors have different pathological and biological characteristics and clinical outcomes indicating that they are separate subsets of cyclin E1(hi) HGSOC. PMID: 30209015
3. Breast cancer recurrence-free interval was significantly worse in patients with cyclin E (LMW-E)-positive tumors who received aromatase inhibitor (AI) neoadjuvant therapy, compared with those with LMW-E negative tumors. PMID: 28947566
4. in a series of human biopsies, non-metastatic SCCs displayed a higher degree of chromosomal alterations and higher expression of the S phase regulator Cyclin E and the DNA damage signal gammaH2AX than the less aggressive, non-squamous, basal cell carcinomas. However, metastatic Squamous cell carcinoma lost the gammaH2AX signal and Cyclin E, or accumulated cytoplasmic Cyclin E. PMID: 28661481
5. Cytoplasmic cyclin E identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes. These patients may benefit from alternative therapies targeting the oncogenic isoforms of cyclin E. PMID: 27881578
6. our results validate the assumption that CBX7 is a tumor suppressor of gliomas. Moreover, CBX7 is a potential and novel prognostic biomarker in glioma patients. We also clarified that CBX7 silences CCNE1 via the combination of CCNE1 promoter and the recruitment of HDAC2. PMID: 28460453
7. Our findings suggest that gene copy-number gain and upregulation of CCNE1 occur in ovarian clear cell carcinoma and are associated with a worse clinical outcome, dictating the survival of early-stage patients. PMID: 27767100
8. YAP/ TAZ pathways contribute to the proliferation/quiescence switch during colon cancer 5FU treatment according to the concerted regulation of Cyclin E1 and CREB PMID: 27527859
9. Silencing of CDCA5 suppresses proliferation of gastric cancer cells by inducing G1-phase arrest via downregulating CCNE1. PMID: 29326043
10. Analysis of genomic data from TCGA demonstrated coamplification of CCNE1 and AKT2 Overexpression of Cyclin E1 and AKT isoforms, in addition to mutant TP53, imparted malignant characteristics in untransformed fallopian tube secretory cells, the dominant site of origin of high-grade serous ovarian cancer PMID: 27663592
11. Finding suggest that amplification of CCNE1 serves as one mechanism for the development of some serous tubal intraepithelial carcinomas. PMID: 27443516
12. Prognostic gene sets based on the 13 genes were developed, and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts. PMID: 28082741
13. Cyclin E1 mRNA and protein expressions were suppressed. PMID: 26603262
14. The opposing effects of ORC1 (represor) and CDC6 (gene activator) in controlling the level of Cyclin E ensures genome stability and a mechanism for linking directly DNA replication and cell division commitment. PMID: 27458800
15. High cyclin E expression is associated with breast cancer. PMID: 28760857
16. High CCNC1 expression is associated with inflammatory breast cancer. PMID: 28107181
17. Inhibition of cell division cycle associated 2 (CDCA2) suppressed the proliferation of lung adenocarcinoma (LAC) cells via G1 phase arrest by downregulating cyclin E1(CCNE1), while overexpression of CDCA2 promoted LAC cells proliferation by upregulating CCNE1. PMID: 28423619
18. a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis PMID: 26279297
19. Amplification of 19q12 CCNE1/URI was found in 10.4% (28/270) and was significantly associated with type II endometrial cancer (EC) high grade, advanced FIGO stage, and aberrant tumor supressor p53 expression. PMID: 27582547
20. Results show that cyclin E1 and CDK2 participate in STC1 promoting cell proliferation of prostate neoplasm cells. PMID: 28350121
21. cyclin E is specifically dephosphorylated at S384 by the PP2A-B56 phosphatase, thereby uncoupling cyclin E degradation from cyclin E-CDK2 activity PMID: 28137908
22. These results provide evidence that ARTD1 regulates cell cycle re-entry and G1/S progression via cyclin E expression and p27(Kip 1) stability independently of its enzymatic activity, uncovering a novel cell cycle regulatory mechanism. PMID: 27295004
23. These results demonstrate a repressor role for NFAT1 in cell cycle progression and Cyclin E expression in B lymphocytes, and suggest a potential function for NFAT1 protein in B cell malignancies. PMID: 27399331
24. High CCNE1 amplification and expression is associated with breast cancer. PMID: 26810187
25. CCNE1/REL gene interaction might play pivotal roles in the occurrence and development of Postmenopausal Osteoporosis. PMID: 26676054
26. These results indicate that miR-25 has anti-apoptosis roles in AGS cells, possibly via inhibiting FBXW7 and thus promoting oncogenes, such as CCNE1 and MYC. PMID: 27120728
27. Cyclin E-driven OvCa cells appeared addicted to glucose metabolism via TCA. Combined CDKi with modalities targeting TCA, like SDHA inhibition showed promising effects for this genotype. Combined blockade of CDK and SDH, both genetically and pharmaceutically, showed synergy and resulted in inhibited proliferation, migration, invasion and migration in A2780 cells PMID: 26826064
28. Over-expression of CCNE1 is associated with non-small cell lung cancer. PMID: 26771237
29. High levels of cyclin E are a predicator of poor prognosis among patients with gastrointestinal cancer. [meta-analysis] PMID: 25627202
30. The effects of CCNE1 knockdown were dependent on the CCNE1 expression status. PMID: 26647729
31. Data show that melanoma antigen, family C, 2 protein (MAGE-C2) binds with RING-box protein 1 (Rbx1) and Cullin 1, and regulates cyclin E stability in melanoma cells. PMID: 26540345
32. The findings suggest that the role of cyclin E and tumor specific low molecular weight isoforms as mediators of tumorigenesis is in part dependent on p53 context. PMID: 26625764
33. Ad-cycE can target cyclin E overexpression in cancer cells and repress tumor growth in syngeneic mouse models. PMID: 26475304
34. ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy PMID: 26204491
35. our findings identify a novel mechanism of cyclin E-mediated Mcl-1 regulation in human cancer PMID: 26219338
36. miR-15b might be involved in termination of osteoblastic cells proliferation by arresting them at G0/G1 phase through direct targeting cyclin E1. PMID: 26007664
37. A significant correlation between cyclin E1 amplification and deletions at a number of the genomic loci in breast cancer. PMID: 25959964
38. These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a, which synergistically retard the growth of human lung cancer cells. PMID: 25909221
39. MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. PMID: 25732226
40. Results show that miR-16 and HuR co-regulate the cyclin E1 mRNA without influencing each other's binding or expression. miR-16 regulation predominates, blocking upregulation of cyclin E1 by HuR. PMID: 25830480
41. Expression of Notch1, -2, and -3, CDK2, and CCNE1 was significantly decreased by upregulation of ALDH1A1 in A549 cells, but increased by its interruption in A549s cells. PMID: 24671051
42. Results show that CCNE1 and BRD4 on chromosome 19 were amplified/overexpressed in a substantial cases of epithelial ovarian cancer with no involvement of BRCA genes. PMID: 25892415
43. This study indicates that CCNE1 rs1406 polymorphism may contribute to BC risk PMID: 25159285
44. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA PMID: 25399696
45. miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of bladder cancer patients PMID: 26057453
46. HOXA7 promotes cell proliferation, and these changes are mediated by cyclin E1/CDK2 PMID: 25501982
47. Aurora-A/HURP relays cell transforming signal to NF-kappaB, and the HURP/NF-kappaB complex is engaged in the regulation of cyclin E1 expression. PMID: 25289861
48. Contrary to previous literature, we found a correlation between cyclin E expression and prognosis. Further large-scale studies are required to confirm our findings. PMID: 26026100
49. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. PMID: 25408144
50. The cell cycleassociated proteins cyclin E and p27kip1 may have contributed to this antitumor effect. PMID: 25310086
顯示更多

收起更多
亞細(xì)胞定位：

Nucleus.
蛋白家族：

Cyclin family, Cyclin E subfamily
組織特異性：

Highly expressed in testis and placenta. Low levels in bronchial epithelial cells.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 1589

OMIM: 123837

KEGG: hsa:898

STRING: 9606.ENSP00000262643

UniGene: Hs.244723

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human